PTO/SB/25(10-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING

Docket Number (Optional)

REJECTION OVER A PENDING SECOND	APPLICATION	CELLTH 3.0-003 CONT CONT XVI
In re Application of: Raymond P. Warrell, Jr., Pier Paolo Pandolfi, and Janice L. Gabrilove		
Application No.: 10/759,290  Filed: January 16, 2004  PROCESS FOR PRODUCING ARSENIC TRIOXIDE FORMULATIONS AND METHODS FOR  For: TREATING CANOES HOME ARSENIC TRIOXIDE FORMULATIONS AND METHODS FOR		
TREATING CANCER USING ARSENIC TRIOXIDE OR MELARSOPROL		
The owner*, Memorial Sloan-Kettering Cancer Center, of 100  percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on the following pending related applications:		
10/758,800 filed on January 16, 2004 10/758,993 filed on January 16, 2004 10/758,994 filed on January 16, 2004 10/759,291 filed on January 16, 2004 10/759,308 filed on January 16, 2004 10/759,313 filed on January 16, 2004 10/759,313 filed on January 16, 2004 10/759,882 filed on January 16, 2004 10/759,882 filed on January 16, 2004		
of any patent on the above-listed pending related applications. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the above-listed pending related applications are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.  In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the above-listed pending applications, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.  Check either box 1 or 2 below, if appropriate.  1 For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency,		
etc.), the undersigned is empowered to act on behalf of the organization.  I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.		
2. X The undersigned is an attorney or agent of record.	hun P. 7-ly Signature	August 31, 2004 Date
Shawn P. Foley - 33,071		
Typed or printed name		
The Commissioner is hereby authorized to charge the disclaimer fee under 37 CFR 1.20(d) to Deposit Account No. 12-1095		
LD-543\512402_1.DOC		